Clinical Observation of Alteplase Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction
10.6039/j.issn.1001-0408.2015.26.36
- VernacularTitle:阿替普酶静脉溶栓治疗急性脑梗死的临床观察
- Author:
Guojun WU
;
Jinchao WANG
;
Lingjun KONG
;
Lei WANG
;
Sheng ZHANG
;
Liyan WANG
;
Zhigang ZHEN
;
Fuxia ZHENG
- Publication Type:Journal Article
- Keywords:
Acute cerebral infarction;
Alteplase;
Intravenous thrombolysis;
Bleeding
- From:
China Pharmacy
2015;(26):3711-3713
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the bleeding,therapeutic efficacy and ADR of patients with acute cerebral infarction (ACI) treated by alteplase intravenous thrombolysis. METHODS:140 ACI patients were randomly divided into group A and B with 70 cases in each group. Group A was give alteplase 0.6 mg/kg for intravenous thrombolytic therapy,and group B was given al-teplase 0.9 mg/kg for intravenous thrombolytic therapy. The bleeding after thrombolysis,bleeding time,therapeutic efficacy and ADR were compared between 2 groups. RESULTS:The incidence of Subcutaneous ecchymosis,gingival bleeding,bleeding of di-gestive tract and intracranial hemorrhage of group A were 4.29%,2.86%,2.86% and 2.86%;those of group B were 14.29%, 12.86%,11.43% and 11.43%;the bleeding time of those symptomsin 2 groups were(6.04±0.75)and(7.22±0.56)h、(24.63± 10.24)and(35.22±9.87)min、(3.04±0.11)and(4.08±0.25)h、(3.12±0.48)和(4.53±0.66)h respectirely,with statistical signifi-cance(P<0.05). There was no statistical significance in therapeutic efficacy and ADR between 2 groups after treatment(P>0.05). CONCLUSIONS:The bleeding should be monitored strictly when ACI patients receive alteplase intravenous thrombolysis,and low-dose alteplase thrombolysis can ultimately reduce the incidence of bleeding.
